SPBC31F10.02 Antibody

What is SPBC31F10.02 and why is it important in S. pombe research?

SPBC31F10.02 is a protein-coding gene in the fission yeast Schizosaccharomyces pombe. It belongs to the same genomic region as other important genes like SPBC31F10.09c (nut2), which encodes the Mediator complex subunit Med10 . S. pombe serves as an excellent model organism for studying eukaryotic cell biology, and proteins in the SPBC31F10 region may be involved in crucial cellular processes including transcription regulation. Understanding these proteins through antibody-based detection provides insights into fundamental biological mechanisms in eukaryotic cells.

What are the recommended validation approaches for confirming SPBC31F10.02 antibody specificity?

When validating SPBC31F10.02 antibody specificity, researchers should employ multiple complementary techniques. The gold standard approach involves testing immunoreactivity against wild-type samples alongside knockout mutants (e.g., testing in SPBC31F10.02Δ strains). This method was effectively demonstrated for Sre1 antibody validation, where specificity was confirmed by loss of immunoreactivity in sre1Δ strains . Additionally, researchers should perform Western blotting using extracts from cells overexpressing the target protein, as was done for Sre1 antibodies . Immunoprecipitation followed by mass spectrometry can provide further validation by confirming the identity of the precipitated protein.

How should researchers select between polyclonal and monoclonal antibodies for SPBC31F10.02 detection?

The choice between polyclonal and monoclonal antibodies depends on the specific research application:

• Polyclonal antibodies recognize multiple epitopes on the target protein, providing stronger signals through amplified detection, making them suitable for applications where sensitivity is paramount. Their generation typically involves immunizing animals with purified protein fragments, similar to the approach used for Sre1 antibodies (amino acids 1-260) .

• Monoclonal antibodies offer higher specificity by recognizing a single epitope, making them preferred for distinguishing between closely related proteins or specific protein conformations. Their production involves more complex procedures including hybridoma technology as demonstrated in the Sre1 monoclonal antibody development, where spleen cells from immunized mice were fused with SP2/0 myeloma cells followed by dilution cloning and isotype determination .

For initial characterization of SPBC31F10.02, using both antibody types in parallel can provide complementary information about protein expression and localization.

What is the optimal protocol for generating specific antibodies against SPBC31F10.02?

The optimal protocol for generating SPBC31F10.02-specific antibodies involves:

• Antigen design and production: Express recombinant SPBC31F10.02 or selected fragments (preferably 100-250 amino acids) with an N-terminal polyhistidine tag and tobacco etch virus (TEV) protease cleavage sequence in E. coli .

• Protein purification: Purify using nickel-nitrilotriacetic acid-agarose followed by TEV protease cleavage to remove the histidine tag .

• Immunization: For polyclonal antibodies, immunize rabbits following standard protocols with the purified antigen. For monoclonal antibodies, immunize BALB/c mice and screen serum for immunoreactivity by ELISA and Western blotting .

• Antibody production: For monoclonal antibodies, isolate spleen cells from immunopositive mice, fuse with SP2/0 myeloma cells, and screen positive clones by ELISA using the immunizing antigen .

• Purification: For polyclonal antibodies, isolate specific antibodies from rabbit serum using affinity chromatography with NHS-Sepharose resin conjugated to the polyhistidine-tagged antigen. For monoclonal antibodies, purify from tissue culture supernatant or ascites fluid using protein-G-Sepharose .

• Validation: Confirm specificity through Western blotting against extracts from wild-type and SPBC31F10.02Δ strains .

How can researchers optimize Western blot protocols for detecting SPBC31F10.02 in S. pombe lysates?

For optimal Western blot detection of SPBC31F10.02 in S. pombe lysates:

• Sample preparation: Grow cells to exponential phase in appropriate media (e.g., YES medium) and collect for protein extraction as described for Sre1 detection protocols .

• Protein quantification: Quantify total protein using the BCA protein assay to ensure equal loading .

• Gel loading verification: Confirm consistent loading by staining the membrane with Ponceau S after electroblotting .

• Primary antibody optimization: Titrate primary antibody concentrations (typically starting at 1:1000 dilution) and incubation conditions (4°C overnight or room temperature for 1-2 hours).

• Detection method selection: Choose between enhanced chemiluminescence with film exposure or infrared imaging systems like Odyssey CLx, depending on required sensitivity and quantification needs .

• Controls: Always include negative controls (deletion strains) and positive controls (overexpression strains) to validate specificity.

• Quantification: For comparative analysis, normalize target protein intensity to loading controls and use appropriate statistical analysis for replicate experiments.

What approaches can be used to develop fusion proteins to enhance SPBC31F10.02 antibody generation?

Developing fusion proteins can significantly enhance antibody generation against challenging targets like SPBC31F10.02. The following approaches have demonstrated effectiveness:

• Protein complex stabilization: If SPBC31F10.02 forms functional complexes with other proteins, creating a fusion protein of the complex components can stabilize the structure during immunization, enhancing antibody generation against conformational epitopes. This approach was successfully implemented by researchers who fused protein complexes to add stability during immunization .

• Scaffold protein fusion: Fusing SPBC31F10.02 to a highly immunogenic scaffold protein can increase immunogenicity while maintaining native conformation.

• Bispecific antibody design: For applications requiring enhanced specificity, consider designing bispecific single-chain antibodies (BscAbs) that can recognize two different epitopes on SPBC31F10.02 or recognize SPBC31F10.02 and another interacting protein simultaneously, similar to the approach used for SARS-CoV-2 antibodies .

• Expression system optimization: Express fusion proteins in E. coli systems for easy production and purification, as demonstrated in the successful production of bispecific single-chain antibodies that exhibited superior antigen-binding properties compared to single-chain variable fragments (scFvs) .

How can SPBC31F10.02 antibodies be employed in phosphoproteome analysis of S. pombe during stress responses?

SPBC31F10.02 antibodies can be valuable tools in phosphoproteome analysis, particularly when examining stress responses in S. pombe:

• Immunoprecipitation for phosphorylation state analysis: Use SPBC31F10.02 antibodies to immunoprecipitate the protein under different stress conditions, followed by phospho-specific detection methods or mass spectrometry to identify differentially phosphorylated residues. This approach can reveal how SPBC31F10.02 phosphorylation status changes under stress conditions, similar to how researchers have analyzed phosphoproteome changes in response to TOR signaling perturbations .

• Sequential immunoprecipitation: For studying protein complexes containing phosphorylated SPBC31F10.02, perform sequential immunoprecipitation using SPBC31F10.02 antibodies followed by phospho-specific antibodies.

• Quantitative phosphorylation analysis: Combine antibody-based enrichment with quantitative mass spectrometry techniques to measure phosphorylation changes across multiple sites on SPBC31F10.02, similar to techniques used to identify significant changes in phosphorylation of specific sites after stress perturbation .

• Integration with global phosphoproteomic data: Correlate SPBC31F10.02 phosphorylation status with broader phosphoproteome changes to position it within signaling networks activated during stress responses.

The table below illustrates how phosphorylation data might be analyzed:

How can researchers develop bispecific antibodies incorporating SPBC31F10.02 recognition for enhanced detection specificity?

Developing bispecific antibodies incorporating SPBC31F10.02 recognition involves:

• Identification of complementary targets: Select a second target protein that functionally interacts with SPBC31F10.02 or is co-expressed in the cellular compartment of interest.

• scFv generation: Generate individual single-chain variable fragments (scFvs) against both SPBC31F10.02 and the second target through standard methods, including protein expression, purification, immunization, and screening .

• Bispecific construct design: Create a bispecific single-chain antibody (BscAb) by genetically linking the two scFvs with an appropriate linker peptide. The construction should allow proper folding of both binding domains, as demonstrated in the successful development of BscAbs against SARS-CoV-2 .

• Expression and purification: Express the BscAb in E. coli and purify using affinity chromatography methods, as this expression system allows for easy production and has been proven effective for bispecific antibodies .

• Binding characterization: Evaluate binding affinity using ELISA and surface plasmon resonance (SPR) to confirm that the BscAb maintains specificity to both targets. BscAbs typically exhibit superior antigen-binding properties than individual scFvs due to increased avidity .

• Functional validation: Verify the enhanced specificity in applications such as immunofluorescence or ChIP assays, where the dual recognition can significantly reduce background and false positives.

What strategies can be employed to study SPBC31F10.02's role in the transcription mediator complex based on its genomic location near known mediator components?

Given SPBC31F10.02's genomic proximity to the mediator complex subunit Med10 (encoded by SPBC31F10.09c/nut2) , several strategies can be employed to investigate its potential role in transcription regulation:

• Co-immunoprecipitation studies: Use SPBC31F10.02 antibodies to immunoprecipitate the protein and associated complexes, followed by Western blotting or mass spectrometry to identify interactions with known mediator complex components.

• Chromatin immunoprecipitation (ChIP): Apply ChIP using SPBC31F10.02 antibodies to identify genomic loci where the protein binds, comparing these with binding sites of known mediator components to establish functional relationships.

• Genetic interaction analysis: Create double mutants combining SPBC31F10.02 deletion with mutations in mediator complex genes, such as med20 or nut2/med10 , to identify synthetic phenotypes suggesting functional relationships.

• Transcriptome analysis: Compare gene expression profiles between wild-type, SPBC31F10.02Δ, and mediator component mutants to identify shared transcriptional signatures.

• Protein localization studies: Use immunofluorescence with SPBC31F10.02 antibodies to determine if the protein colocalizes with mediator complex components during transcription.

• Rescue experiments: Test whether overexpression of mediator components can rescue phenotypes of SPBC31F10.02 deletion and vice versa, similar to approaches used to test functional relationships in other S. pombe studies .

How should researchers address cross-reactivity issues when using SPBC31F10.02 antibodies?

When encountering cross-reactivity with SPBC31F10.02 antibodies, researchers should implement a systematic troubleshooting approach:

• Validation in knockout strains: If cross-reactivity is suspected, confirm by testing antibody reactivity in SPBC31F10.02Δ strains. Any remaining signal indicates cross-reactivity with other proteins, a strategy effectively used for validating Sre1 antibodies .

• Epitope mapping: Determine which regions of SPBC31F10.02 are recognized by the antibody and analyze sequence similarity of these regions with other S. pombe proteins to identify potential cross-reactive targets.

• Antibody purification: Implement additional purification steps such as:

  • Affinity purification against recombinant SPBC31F10.02 antigen

  • Negative selection against cross-reactive proteins

  • Preabsorption of antibody solutions with lysates from SPBC31F10.02Δ strains

• Alternative antibody development: Generate new antibodies against different regions of SPBC31F10.02 with lower sequence homology to other proteins.

• Competitive binding assays: Use competitive ELISA methods to verify epitope specificity, similar to approaches used for confirming distinct binding sites of different antibodies to the same target .

• Isotype determination and optimization: Determine the antibody isotype and optimize purification methods accordingly, such as using protein-G-Sepharose for IgG purification .

What controls are essential when performing immunoprecipitation experiments with SPBC31F10.02 antibodies?

For rigorous immunoprecipitation experiments with SPBC31F10.02 antibodies, the following controls are essential:

• Input control: Analyze a small portion (2-5%) of the pre-immunoprecipitation lysate to verify target protein presence and establish a reference for enrichment calculation.

• Negative genetic control: Include lysate from SPBC31F10.02Δ strains to identify non-specific bands or contaminating proteins.

• Isotype control: Use matched isotype antibodies from the same species but targeting an irrelevant protein to identify non-specific binding to the antibody class itself.

• Beads-only control: Perform the immunoprecipitation procedure without primary antibody to identify proteins binding non-specifically to the beads or matrix.

• Competitive peptide control: Pre-incubate the antibody with excess purified SPBC31F10.02 protein or peptide epitope before immunoprecipitation to confirm signal specificity.

• Cross-linking validation: If using cross-linking approaches, include non-cross-linked samples to distinguish true interactions from artifacts.

• Reciprocal immunoprecipitation: For protein-protein interaction studies, confirm interactions by immunoprecipitating with antibodies against the interacting partner and blotting for SPBC31F10.02.

• RNase/DNase treatment controls: Include these treatments to distinguish RNA/DNA-mediated interactions from direct protein-protein interactions.

How can researchers quantitatively assess SPBC31F10.02 antibody affinity and compare different antibody preparations?

Quantitative assessment of SPBC31F10.02 antibody affinity involves several complementary approaches:

• Surface Plasmon Resonance (SPR): This gold standard technique can determine the equilibrium dissociation constant (KD) by immobilizing SPBC31F10.02 protein on a sensor chip and flowing different concentrations of antibody over the surface. Values in the nanomolar range (e.g., 100-300 nM) indicate good affinity, comparable to the KD values reported for other antibodies .

• Enzyme-Linked Immunosorbent Assay (ELISA): Perform dose-response curves with serial dilutions of antibody against coated SPBC31F10.02 protein. Calculate EC50 values to compare relative affinities between different antibody preparations .

• Bio-Layer Interferometry (BLI): This label-free technique can measure association and dissociation rates in real-time, providing kon and koff values to calculate KD.

• Isothermal Titration Calorimetry (ITC): This technique measures the heat released or absorbed during binding to determine binding affinity and thermodynamic parameters.

• Competitive binding assays: Measure the ability of unlabeled antibody to compete with a labeled reference antibody for binding to SPBC31F10.02, providing IC50 values for comparison.

When comparing different antibody preparations, standardize testing conditions and use the same antigen batch to ensure valid comparisons. Report confidence intervals with affinity measurements and validate with multiple technical replicates.

How should researchers interpret changes in SPBC31F10.02 levels or modifications in response to cellular stress?

When interpreting changes in SPBC31F10.02 levels or modifications during stress responses:

• Establish appropriate baselines: Compare stress conditions to multiple time points in unstressed controls to distinguish stress-specific responses from normal fluctuations.

• Consider kinetics: Analyze multiple time points after stress induction to capture transient responses, as protein modifications can show complex temporal patterns similar to those observed in phosphoproteome studies .

• Validation across multiple stress types: Test whether changes are specific to particular stressors or represent general stress responses by comparing across conditions such as nutrient limitation, oxidative stress, and TOR inhibition .

• Correlation with phenotypic outcomes: Link molecular changes to physiological parameters, such as growth rate, cell morphology, or stress resistance, similar to approaches used in studies of non-essential S. pombe genes .

• Integrate with pathway analysis: Position SPBC31F10.02 within known stress-response pathways by comparing its dynamics with those of established pathway components. This is particularly relevant if SPBC31F10.02 is related to transcription regulation through the mediator complex .

• Statistical robustness: Apply appropriate statistical tests with correction for multiple comparisons when analyzing large datasets, and report both fold changes and p-values for significance assessment, as exemplified in phosphoproteome studies .

• Consideration of post-translational modification crosstalk: Analyze how different modifications on SPBC31F10.02 (phosphorylation, ubiquitination, etc.) interact and influence each other during stress responses.

What bioinformatic approaches can help predict the function of SPBC31F10.02 based on its sequence and relationship to characterized proteins?

Several bioinformatic approaches can help predict SPBC31F10.02 function:

• Sequence homology analysis: Compare SPBC31F10.02 sequence with characterized proteins across species using BLAST and HMMer to identify conserved domains and potential functions.

• Structural prediction: Use tools like AlphaFold or I-TASSER to predict protein structure and identify potential functional sites through structural similarity to known proteins.

• Protein interaction network analysis: Integrate SPBC31F10.02 into protein interaction networks based on:

  • Experimental data from high-throughput studies

  • Co-expression patterns across conditions

  • Genomic proximity to functionally related genes like the mediator complex subunit Med10

• Evolutionary analysis: Perform phylogenetic profiling to identify proteins with similar evolutionary patterns, suggesting functional relationships.

• Function prediction algorithms: Apply machine learning approaches that integrate multiple data types (sequence, structure, expression, genetic interactions) to predict protein function.

• Domain-based annotation transfer: Identify specific domains in SPBC31F10.02 and infer functions based on the known roles of these domains in other proteins.

• Pathway enrichment analysis: Analyze whether proteins with similar patterns of regulation are enriched in particular pathways, similar to the approach used in phosphoproteome studies .

• Genetic interaction prediction: Use computational methods to predict genetic interactions based on known interaction patterns of genes with similar characteristics.

How can researchers integrate antibody-based detection of SPBC31F10.02 with other omics approaches for comprehensive functional characterization?

Integrating antibody-based detection with other omics approaches provides comprehensive characterization of SPBC31F10.02:

• Immunoprecipitation coupled with mass spectrometry (IP-MS): Use SPBC31F10.02 antibodies to pull down the protein and its interacting partners for identification by mass spectrometry, creating a protein interaction network.

• ChIP-seq integration: Combine chromatin immunoprecipitation using SPBC31F10.02 antibodies with next-generation sequencing to map genomic binding sites, then integrate with:

  • Transcriptome data (RNA-seq) to correlate binding with gene expression changes

  • Other ChIP-seq datasets to identify co-binding with transcription factors or mediator components

  • Chromatin accessibility data (ATAC-seq) to understand chromatin context

• Phospho-specific antibody applications: Develop phospho-specific antibodies against identified SPBC31F10.02 phosphorylation sites and use them in parallel with phosphoproteomics to validate and quantify specific modifications during stress responses .

• Spatial proteomics integration: Combine immunofluorescence using SPBC31F10.02 antibodies with high-content imaging and subcellular fractionation proteomics to create a spatiotemporal map of protein localization and interactions.

• Multi-omics data integration: Apply computational approaches to integrate antibody-based quantification of SPBC31F10.02 with:

  • Transcriptomics data to correlate protein levels with mRNA expression

  • Metabolomics data to link SPBC31F10.02 function to metabolic changes

  • Phenomics data to associate molecular changes with cellular phenotypes

• Network-based analysis: Position SPBC31F10.02 within cellular networks by combining antibody-based interaction data with genetic interaction networks and computational predictions.

• Temporal dynamics studies: Use antibody-based detection in time-course experiments combined with other omics approaches to understand the temporal order of events involving SPBC31F10.02 during cellular processes.